Back to top

gene-therapy: Archive

Zacks Equity Research

bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well

bluebird (BLUE) beats sales estimates in the first quarter on increased Zynteglo product revenues. The company is on track with the ongoing launch of its gene therapies.

VRTXNegative Net Change HTGCPositive Net Change BLUEPositive Net Change CRSPPositive Net Change